On September 10, 2024, Director Timothy Scannell sold 5,000 shares of Insulet Corp (PODD, Financial) as reported in a recent SEC Filing. Following this transaction, the insider now owns 30,586 shares of the company.
Insulet Corp, headquartered in Acton, Massachusetts, is a medical device company primarily engaged in the development, manufacture, and sale of insulin infusion systems for people with insulin-dependent diabetes.
Over the past year, Timothy Scannell has sold a total of 15,300 shares of Insulet Corp and has not made any purchases of the stock. This recent transaction is part of a broader trend observed within the company, where there have been 13 insider sells and only 2 insider buys over the past year.
Shares of Insulet Corp were trading at $225.84 on the day of the sale. The company has a market cap of approximately $16.00 billion. The price-earnings ratio of the stock stands at 41.50, which is above the industry median of 26.16.
According to the GF Value, the intrinsic value of Insulet Corp's stock is estimated at $374.14, suggesting that the stock is significantly undervalued with a price-to-GF-Value ratio of 0.6.
This valuation is based on historical trading multiples, an adjustment factor from GuruFocus based on past returns and growth, and future business performance estimates from Morningstar analysts.
The insider's recent sale could be of interest to current and potential investors, providing insights into insider confidence and valuation perspectives at current price levels.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
